Physician

Thomas Lambert, MD

According to 2025 Medicare claims, Thomas Lambert, MD (NPI: 1225252489) practices dermatology in the Tyler, TX market, with the plurality of this provider's patient population coming from Smith, TX. This provider's primary affiliated billing organization is EPIPHANY DERMATOLOGY PA (NPI: 1043615263; TIN: 47-2190514) and primary practice location at 75703-0585.

Lambert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,654 traditional Medicare patients, billed 11,944 HCPCS/CPT codes, and received $477,501 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,769 prescription claims across 704 beneficiaries totaling $1,054,310 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 6 records totaling $99. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $151,564 to $477,501. Similarly, Part D prescription costs have moved sharply higher in recent years, from $116,825 to $1,054,310. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$241K$483K2015 Medicare payment: $151,564 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $174,975 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $271,100 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $343,241 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $382,454 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $281,326 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $367,398 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $393,336 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $482,632 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $477,501 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20159134,652$151,564
20167203,901$174,975
20171,2627,172$271,100
20181,5919,276$343,241
20191,7079,793$382,454
20201,5297,604$281,326
20211,5818,719$367,398
20221,6189,803$393,336
20231,67211,731$482,632
20241,65411,944$477,501

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$527K$1.1M2015 Drug cost: $116,825 (USD; Tot_Drug_Cst)2016 Drug cost: $72,901 (USD; Tot_Drug_Cst)2017 Drug cost: $195,650 (USD; Tot_Drug_Cst)2018 Drug cost: $194,446 (USD; Tot_Drug_Cst)2019 Drug cost: $277,836 (USD; Tot_Drug_Cst)2020 Drug cost: $587,574 (USD; Tot_Drug_Cst)2021 Drug cost: $911,984 (USD; Tot_Drug_Cst)2022 Drug cost: $905,539 (USD; Tot_Drug_Cst)2023 Drug cost: $786,237 (USD; Tot_Drug_Cst)2024 Drug cost: $1,054,310 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015382863$116,825
2016318802$72,901
20175351,512$195,650
20186861,914$194,446
20198132,153$277,836
20207091,987$587,574
20218142,199$911,984
20227511,964$905,539
20236971,777$786,237
20247041,769$1,054,310

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths365414$78
11102Biopsy of related skin growth, first growth8811,136$64
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,2271,950$61
17000Destruction of precancer skin growth, 1 growth9711,435$37
17003Destruction of precancer skin growth, 2-14 growths7975,092$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Humira(Cf) PenAdalimumab25700$236,369
Dupixent PenDupilumab471,540$204,890
Dupixent SyringeDupilumab21588$77,398
RinvoqUpadacitinib12360$75,936
OtezlaApremilast14420$65,601

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.6$99GENZYME CORPORATION
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Thomas Lambert, MD?

Tedicare shows public-source Medicare data for Thomas Lambert, MD (NPI 1225252489), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas Lambert, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Thomas Lambert, MD?

Thomas Lambert, MD is linked to EPIPHANY DERMATOLOGY PA (billing NPI 1043615263) in the available physician profile data.

Does Thomas Lambert, MD have Open Payments data?

Thomas Lambert, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.